Department of Gynecologic Oncology, University Hospital La Fe, València, Spain
Department of Nuclear Medicine, University Hospital La Fe, València, Spain.
Int J Gynecol Cancer. 2019 Feb;29(2):377-381. doi: 10.1136/ijgc-2018-000049. Epub 2018 Dec 21.
There is limited evidence favoring the use of the sentinel lymph node technique in ovarian cancer, and no standardized approach has been studied. The objective of the present pilot study is to determine the feasibility of the sentinel lymph node technique by applying a clinical algorithm.
Patients with confirmed ovarian cancer were included. 99mTc and indocyanine green were injected into the ovarian and infundubulo-pelvic ligament stump. A gamma probe and near-infrared fluorescence imaging were used for sentinel lymph node detection.
The sentinel lymph node technique was performed in nine patients with a detection rate in the pelvic and/or para-aortic region of 100%. The tracer distribution rates of sentinel lymph nodes in the pelvic and para-aortic regions were 87.5% and 70%, respectively.
The detection of sentinel lymph nodes in early-stage ovarian cancer appears to be achievable. Based on these results, a clinical trial entitled SENTOV (SENtinel lymph node Technique in OVarian cancer) will be performed.
在卵巢癌中，使用前哨淋巴结技术的证据有限，且尚未研究出标准化的方法。本研究旨在通过应用临床算法，确定前哨淋巴结技术的可行性。
纳入经确诊的卵巢癌患者。将 99mTc 和吲哚菁绿注射到卵巢和输卵管-卵巢韧带残端。使用伽马探针和近红外荧光成像来探测前哨淋巴结。
9 例患者成功实施了前哨淋巴结技术，盆腔和/或腹主动脉区域的检测率为 100%。盆腔和腹主动脉区域的前哨淋巴结示踪剂分布率分别为 87.5%和 70%。
早期卵巢癌中前哨淋巴结的检测似乎是可行的。基于这些结果，一项名为 SENTOV（卵巢癌前哨淋巴结技术）的临床试验即将开展。
